Recently, Yuning Chen, Ph.D., from Creative Biolabs was exclusively interviewed by Angelo DePalma, a journalist from Biocompare, and shared his forward-looking and professional view on antibody-drug conjugates( ADCs). Antibody-drug conjugates (ADCs) are a new implementationRead More…
Tagworks Pharmaceuticals in the University of Nijmegen Medical Center has developed a new technology that targets tumor to deliver chemotherapy drugs in extreme cases. By controlling the “click release” of a chemotherapeuticRead More…
Still reeling from the failure of its lead breast cancer candidate glembatumumab vedotin last month, Celldex has culled another two pipeline projects and now says it will focus its R&D efforts mainlyRead More…
“Understanding cancer heterogeneity could further reduce chemo use,” says cancer research expert Antonio Giordano, MD, PhD, Director of the Sbarro Institute for Cancer Research and Molecular Medicine at Temple University. “Further studyRead More…
The FORWARD I Phase III registration trial (NCT02631876) evaluating the antibody-drug conjugate or ADC mirvetuximab soravtansine as a single-agent therapy for the treatment of platinum-resistant ovarian cancer, has completed full enrollment andRead More…
A Simple Concept of Antibody-drug Conjugates (ADCs) Developing new anticancer chemotherapeutic drugs showing superior antitumor efficacy with reduced toxicity is continuing to be a challenging endeavor. Antibody-drug conjugates (ADCs) are an emergingRead More…
The concept of antibody–drug conjugates (ADCs) is based on exploiting the high specificity of a monoclonal antibody toward a selected tumor cell-surface antigen and enhancing the cell-killing capacity of the antibody byRead More…
Antibody-drug conjugates or ADCs have emerged as a powerful and strategic tool in the targeted treatment of cancer. These relatively novel agents combine the ability of monoclonal antibodies to specifically target tumor cells,Read More…
With breakthrough designation from the FDA and priority medicine status in the EU, expectations for Roche’s antibody-drug conjugate for non-Hodgkin lymphoma polatuzumab vedotin are running pretty high. Phase 2 data presented atRead More…
A leader in the expanding field of antibody-drug conjugates or ADCs for the treatment of cancer, Immunogen last week highlighted some of the company’s the operating results for 2017. Immunogen is a clinical-stage biotechnologyRead More…